---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046101"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:48:23.901058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M

## Summary
- Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).
- FY2025 total product revenue guidance revised to $250-300M reflecting launch dynamics and ATC growth trajectories.
- Cash and investments $366M as of March 31, 2025; expected to fund operations into second half of 2026.
- Q1 manufacturing capacity reduced by annual maintenance; fully resumed, targeting 100-110 commercial infusions in Q2.
- On track for Amtagvi regulatory approvals in UK, EU, Canada in 2025; NSCLC registrational data in 2H25.

## SEC filing metadata
- accession: 0001104659-25-046101
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/0001104659-25-046101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046101
- JSON: https://secwatch.observer/filing/0001104659-25-046101.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.